AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 193.32B -1.4% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.63 |
| Forward PE | 15.29 |
| Dividend | 2.39 (1.92%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 319,389 |
| Open | 12,400 |
| Previous Close | 12,400 |
| Day's Range | 12,390 - 12,480 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 15,793.78 (+26.72%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,794p, which is an increase of 26.72% from the latest price.
News
AstraZeneca Partners With Oracle to Refine Clinical Research With AI
AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for ...
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI (durvalumab), TAGRISSO (osimertinib) and savolitinib
AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, O...
AstraZeneca announces new data across portfolio at ESMO 2026
AstraZeneca (AZN) announces new data across its portfolio and pipeline at the European Society for Medical Oncology, ESMO, Congress, 23-27 October 2026. Highlights include: CLARITY-Gastric01: Phase II...
Covid vaccine victim ‘not disabled enough’ for compensation
Marie-Claire Hoyle lost use of her hands and was numb from collarbone to thigh after receiving AstraZeneca jab during 2020 trial
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.
AstraZeneca (AZN) Partners with insitro in $1.5B AI-Driven Drug Discovery Collaboration
AstraZeneca (AZN) Partners with insitro in $1.5B AI-Driven Drug Discovery Collaboration
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets.
Insitro, AstraZeneca Sign AI Drug Discovery Deal
(RTTNews) - Thursday, insitro announced a strategic collaboration with AstraZeneca (AZN) to use artificial intelligence to discover new treatments for metabolic dysfunction-associated steatohepatitis ...
AstraZeneca enters drug discovery collab, licensing agreement with insitro
AstraZeneca (AZN) announced that it has entered into a new strategic drug discovery collaboration and licensing agreement with insitro, a leading artificial intelligence therapeutics company. Using ad...
AstraZeneca PLC (AZN) Shares Surge 4.0% -- What GF Score of 76 Tells Investors
AstraZeneca PLC (AZN) Shares Surge 4.0% -- What GF Score of 76 Tells Investors
Top Research Reports for Mastercard, AstraZeneca & Sandisk
Mastercard's payment growth, AstraZeneca's drug pipeline and Sandisk's AI-driven SSD demand headline today's top research reports, revealing key growth drivers and risks for investors.
Wednesday's ETF Movers: PPH, SILJ
In trading on Wednesday, the VanEck Pharmaceutical ETF is outperforming other ETFs, up about 2.9% on the day. Components of that ETF showing particular strength include shares of Astrazeneca, up about...
AstraZeneca upgraded to Buy from Sell at Nordea
Nordea double upgraded AstraZeneca (AZN) to Buy from Sell with a price target of SEK 1,900, up from SEK 1,650. The firm sees investor focus returning to the company’s heart…
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research ann...
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for h...
AstraZeneca Transcript: AZN Meet The Management at ASBMR 2026
Efzimfotase alfa missed HICKORY’s week-25 Six-Minute Walk Test primary endpoint, but showed benefits across pain, fatigue and function, with continued gains in the extension. Peak sales guidance remains $3B–$5B; FDA priority review covers the full dataset.
AstraZeneca Slides: FY 2026
AstraZeneca has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 12, 2026.
AstraZeneca Young Health Programme and UNICEF partner to advance health equity in Thailand
AstraZeneca has announced a total investment of more than US$100 million in its Young Health Programme (YHP) between 2010 and 2030, supporting its commitment to advancing health equity in more than 60...
Efzimfotase Alfa Shows Encouraging Trend in HPP Trial; AstraZeneca (AZN) Dividend Remains Attractive
Efzimfotase Alfa Shows Encouraging Trend in HPP Trial; AstraZeneca (AZN) Dividend Remains Attractive
AstraZeneca announces ALXN1850 did not achieve statistical significance
Results from the HICKORY Phase III trial showed that efzimfotase alfa, ALXN1850, did not achieve statistical significance but demonstrated a numerical improvement in the primary endpoint of Six-Minute...
Guardant Health Announces Approval in Europe of Guardant360 CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as ...
Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Genetics to Advance Prostate Cancer ...
Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Genetics to Advance Prostate Cancer Genomic Testing
SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
(RTTNews) - SOPHiA GENETICS (SOPH) and Myriad Genetics, Inc. (MYGN) announced Thursday a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support p...
Myriad, Sophia advance prostate cancer-specific genomic instability score tech
Myriad Genetics (MYGN) and Sophia Genetics (SOPH) announced a collaboration to advance new prostate cancer-specific genomic instability score technology to support precision oncology approaches with A...